ClinicalTrials.Veeva

Menu

Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)

Pfizer logo

Pfizer

Status

Conditions

Severe Uncontrolled Atopic Dermatitis

Treatments

Drug: abrocitinib

Study type

Expanded Access

Funder types

Industry
Other

Identifiers

Details and patient eligibility

About

Provide pre-approval single patient Expanded Access (compassionate use) of abrocitinib for patients with severe uncontrolled atopic dermatitis

Full description

In Expanded Access, treating physicians are the Sponsor.

Expanded Access requests from treating physicians may be submitted at www.pfizercares.com ; availability will depend on location/country.

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Must have severe uncontrolled atopic dermatitis refractory to other available treatments

Trial contacts and locations

0

Loading...

Central trial contact

Pfizer Cares

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems